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Introduction
Dabigatran, an oral direct thrombin inhibitor 1 , is the first novel oral anticoagulants (NOACs) approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Unlike traditional oral anticoagulant warfarin, dabigatran has a predictable pharmacokinetic profile and does not require frequent blood monitoring. In the Randomized
Evaluation of the Long-Term Anticoagulation Therapy (RE-LY) trial, dabigatran 150mg twice daily was superior to warfarin in the prevention of stroke and systemic embolism in AF patients and non-inferior to warfarin at 110mg twice daily. 2 Despite its comparable efficacy and relative convenience, several randomized controlled trials and reports have demonstrated that the risk of gastrointestinal bleeding (GIB) is higher with the use of dabigatran than traditional therapies across different indications. [2] [3] [4] [5] A recent systematic review on previous clinical trials demonstrated that the pooled odds ratio (OR) of GIB associated with dabigatran use was 1.6 when compared to traditional therapies including warfarin. 6 Recently, the U.S. Food and Drug Administration (FDA) released a safety announcement that dabigatran is associated with a higher rate of gastrointestinal bleeding compared with warfarin in patients with non-valvular AF, based on their latest analysis of the Mini-Sentinel database. 7 However, the actual bleeding risk of dabigatran use for various indications in daily clinical practice outside restrictive clinical trial setting is less well described.
Although current guidelines recommend that proton pump inhibitors (PPIs) should be considered in patients at high risk of GIB receiving antithrombotic therapy, 6, [8] [9] [10] the role of gastroprotective agents including PPIs and histamine type-2 receptor antagonists (H2RAs) in the prevention of GIB associated with dabigatran remains undefined.
This study determined the risk of GIB in patients newly prescribed with dabigatran in a large population based retrospective cohort study from Hong Kong. We also identified the risk factors and the effects of gastroprotective agents in dabigatran associated GIB in this cohort.
Method Data source
This study used the electronic medical records of the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (HA), which is the sole public-funded healthcare provider of Hong Kong. The HA is currently serving a population of over seven million, managing 42 hospitals, 47 Specialist Out-patient Clinics, and 73 General Out-patient Clinics organized into seven hospital clusters according to geographical locations. 11 The HA uses the Clinical Management System (CMS), a computerized clinical management system, to record all key clinical information such as treatment, diagnoses, prescriptions, laboratory results and procedures information; and to write consultation and discharge summaries. 12 It also allows clinicians and health care specialists to order and review care in their daily practice. 13 Electronic patient records in the HA, including demographics, date of consultation, date of hospital admission and discharge, diagnoses, procedures, drug prescriptions and laboratory tests were transferred from CMS to CDARS for audit and research propose. 13 CDARS has been used for conducting high quality population-based studies. [13] [14] [15] [16] [17] A local study demonstrated a high accuracy of coding in CDARS with a positive predictive value of 90%. 18 Nonetheless, we conducted further validation on a sample of patients in this cohort to ensure the validity of our dataset.
All patient records in CDARS are anonymized to protect patient confidentially. A unique reference number is allocated for each individual patient to facilitate data retrieval and further analysis. The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number: UW 13-468).
Informed consent from patients was not required since the data used in this study were anonymized.
Study design
This is a retrospective cohort study. We identified all patients who were newly prescribed with dabigatran between 1 st Jan 2010 and 31 st Dec 2013 from the CDARS. The index date was defined as the date of the first dabigatran prescription. The follow-up of each patient was commenced from the index date until the development of GIB, death, the prescription of an alternative anticoagulant (warfarin, rivaroxaban or apixaban), the end of the study period (31 st Dec 2013) or 30 days after discontinuation (defined as >30 days of interval between prescription refills) of dabigatran, whichever came first. Another 30-day follow-up was added after the final prescription of dabigatran to account for non-compliance and capture any GIB that may have led to treatment discontinuation. Patients who had received dabigatran in the 12 months prior to the index date and patients who were prescribed other anticoagulants on the index date were excluded. Patient's coexisting medical illnesses prior to the index date and drugs concurrently prescribed in the follow-up period were retrieved from the CDARS (Figure 1 ).
Outcome and covariates
The primary outcome was the development of GIB after the prescription of dabigatran. Patients who developed GIB were identified in CDARS with the physician assigned International Table 1 ).
The use of the following medications during follow-up was included as covariates in terms of dichotomous variables (present/absent) in the analysis (Figure 1 ): use of aspirin, clopidogrel, nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), histamine type-2 receptor antagonists (H2RAs), and selective serotonin reuptake inhibitors (SSRIs). [19] [20] [21] [22] [23] Baseline medical conditions including prior ischemic stroke/transient ischemic attack/systemic embolism, renal disease, and prior history of peptic ulcer/GIB were also counted as dichotomous covariates in the analysis. [20] [21] [22] For each patient, all diagnosis records dated prior to the individual index date were retrieved using ICD-9 codes (Supplementary Table 1 ) from CDARS for the identification of the baseline medical conditions.
Data validation
To validate the coding accuracy, we extracted the original medical records in the CMS of a sample of patients (Supplementary Figure 1) from the Hong Kong West (HKW) cluster, which is one of the seven hospital clusters (a group of hospitals under the same management structure in a region of Hong Kong) of the HA. The HKW cluster comprises seven hospitals, one specialist rehabilitation center, and six general out-patient clinics in the Central & Western District and the Southern District of Hong Kong. 24 The HKW cluster region has a population of over half a million, representing about 8% of the Hong Kong population. 24 The age and gender distribution in the HKW cluster region are similar to that of the overall population in Hong Kong. 25 The HKW cluster also provides services to patients residing outside its cluster region through crosscluster referrals. In particular, it hosts one of the two university teaching hospitals in Hong Kong, the Queen Mary Hospital, which is a tertiary referral center for all complex cases. 24 A gastroenterologist (WKL) manually reviewed the patient records to validate the diagnosis of GIB (Supplementary Table 1 ). The identifications of two important patient characteristics were also validated in our cohort from CDARS -prior history of peptic ulcer/GIB and history of AF 
Statistical analysis
Continuous variables were reported as mean ± standard deviation whereas categorical data were expressed as frequencies (percentages), respectively. Risk time was measured from the index date when dabigatran was prescribed until the development of GIB. Conditional Poisson regression was used to determine the risk of GIB, in terms of incidence rate ratio (IRR) with 95% confidence intervals (CI), among patients who were taking dabigatran after controlling for baseline medical conditions and use of concurrent medications. Patients who had a prescription of either H2RA and/or PPI during follow-up (regardless of the duration of medication) were defined as users of gastroprotective agents. Subgroup analyses were conducted by classifying patients into three groups according to their drug exposures: 1) H2RA only; 2) PPI only; and 3) both H2RA and PPI (either prescribed simultaneously or sequentially).
The times to GIB for users and non-users of gastroprotective agents were illustrated by KaplanMeier curves and compared using the Cox proportional hazards regression model in hazard ratios (HR), with adjustment for baseline characteristics and use of concurrent medications as previously mentioned.
We conducted further subgroup analysis to examine the effect of gastroprotective agents in new OAC "starters" and "switchers" from other OACs, since they may have different bleeding risks. 26 A patient was classified as a "switcher" if they were prescribed warfarin, rivaroxaban or apixaban within 3 months prior to index date. We also performed subcategory analyses to assess the effects of gastroprotective agents for upper GIB and non-upper GIB. Since a number of case reports revealed an early onset of dabigatran-associated GIB, [27] [28] [29] [30] we conducted an additional analysis to evaluate the protective effect of gastroprotective agents on early bleeding defined as occurring within 30 days since commencement of dabigatran. For this analysis, only the first 30 days since dabigatran commencement were included.
A two-sided p-value <0.05 was considered as statistically significant. Statistical Analysis System (SAS) v9.3 (SAS Institute Inc., Cary, North Carolina) was used for statistical analysis.
Sensitivity analysis
Several additional analyses were conducted to test the robustness of the main results. Since oral anticoagulants could exacerbate bleeding from underlying lesions, patients with prior history of peptic ulcer/GIB may be at higher risk of GIB. 6, 22 Therefore, in the first sensitivity analysis, we stratified the patients by prior history of peptic ulcer/GIB to explore the effect of gastroprotective agents in different risk groups. Another analysis was conducted by inclusion of AF patients only, which is the most common indication for dabigatran. The third sensitivity analysis accounted for the dosage effect of dabigatran on GIB by including the average daily dose as a covariate in an additional analysis. Finally, additional analyses were performed by stratifying the users of gastroprotective agents into patients who were continuously prescribed gastroprotective agents (continuous users), defined as those with a recorded supply of medication for ≥80% of the days of follow-up; and those who were not continuous users (i.e. infrequent users).
Results
Data validation
Among the 5,041 patients on dabigatran included in this study, 711 (14.1%) patients were from the HKW cluster (Supplementary Figure 1) . Of these, we selected all patients who had a diagnosis of GIB (n=35), all patients who had prior history of peptic ulcer/GIB (n=78), and a random sample of 133 (20%) patients who had AF. As negative controls, we selected a random sample of 66 (10%) patients who did not develop GIB, a random sample of 63 (10%) patients who did not have prior history of peptic ulcer/GIB, and all patients who did not have AF (n=32).
There were 63 patients being selected for validation of two medical conditions, and 8 patients being selected for validation of three medical conditions due to the random nature of the sample selection. The final validation sample consisted of 328 patients. The corresponding PPVs and NPVs were: GIB, PPV=100%, NPV=98%; prior history of peptic ulcer/GIB, PPV=90%, NPV=92%; AF, PPV=95%, NPV=91%.
Patient characteristics
In total, 5,206 patients received dabigatran during the study period. Of these, five patients had dabigatran prescription(s) within one year prior to index date and were excluded. Further, 160
patients who were being prescribed other oral anticoagulants on the index date were removed.
The final analysis included 5,041 patients. The most common indication for dabigatran was AF (88.3%). The mean age of the patients was 72.0±10.9 years and 47.8% were male. The mean follow-up was 215±255 days and the total follow-up was 2,973 patient-years. Baseline characteristics of the patients are presented in Table 1 .
Risk of gastrointestinal bleeding
There were 124 patients (2.5%) who developed GIB during follow-up. All cases were hospitalized with a diagnosis of GIB. Of these, 93 (75%) patients were admitted to hospital with GIB, and the remaining 31 (25%) patients developed GIB during hospitalization. Among all users of gastroprotective agents, about 70% used the drugs continuously during follow-up (Table 4) . A reduction of the risk of GIB was observed among these patients as estimated by IRR (0.51; 95%CI, 0.34-0.77) and HR (0.57; 95%CI, 0.38-0.87). The effects of gastroprotective agents among the infrequent users were not statistically significant in general (Table 4) .
Discussion
Gastrointestinal bleeding is a major adverse clinical outcome associated with the use of the NOACs. In particular, the bleeding risk appears to be higher for dabigatran when compared to other NOACs. 6 As there is currently no effective antidote for dabigatran, patients are potentially at a higher risk of uncontrolled GIB as compared with warfarin, which can be reversed by vitamin K and fresh frozen plasma. This would highlight the importance of identifying a preventive strategy for GIB in patients taking dabigatran. This is the first population-based study that determines the role of gastroprotective agents on the risk of GIB among patients newly prescribed with dabigatran. We used the central electronic patient record database of the HA of Hong Kong which covers about 80% of all hospital admissions in Hong Kong. 31 We found that the concomitant use of gastroprotective agents, including PPIs and H2RAs, significantly reduced the risk of GIB by 48% among patients on dabigatran. Of particular importance is that only patients with a history of peptic ulcers or GIB, who were considered a high-risk group for GIB, were found to be significantly protected by gastroprotective agents. While NOAC could result in bleeding from small bowel or lower GI tract, our sub-analysis showed that the protective effect was statistically significant for upper GIB only. The results were also consistent for all sensitivity analyses, including testing on different indications and dosage effects of dabigatran and prior OAC experience.
In this study, we found that old age (age≥75), a history of peptic ulcer/GIB and the concomitant use of aspirin were associated with higher risk of GIB among dabigatran users. This is consistent with previous observations that age and prior history of peptic ulcer/GIB are associated with higher risk of GIB among patients using NSAIDs or aspirin. [32] [33] [34] Since many AF patients would have concurrent ischemic heart disease that would require aspirin, our data are supportive of further increase in risk of GIB when aspirin and dabigatran is co-administered. Particular caution is therefore mandatory in this group of patients who require both antiplatelet and anticoagulant therapies.
Notably, we found that 67.5% of the dabigatran users in this cohort were concurrently prescribed gastroprotective agents. While a similar prescription rate was observed in the AF patients in Italy (65.3%) 35 , the prescription rate is higher than those reported in the RE-LY trial (17.6%) 2 and other observation studies in the United States (24%) 36 and Denmark (13.4%) 37 . A plausible explanation of the high prescribing rate is that clinicians may be more cautious about peptic ulcer disease and bleeding since gastrointestinal disorders is one of the most common diseases requiring hospital admission in Hong Kong. 31 When compared to the West, Hong Kong has a higher prevalence of peptic ulcer disease. [38] [39] [40] Therefore, it is possible that clinicians in Hong
Kong have a higher tendency of prescribing gastroprotective agents compared to other countries.
Further, medications in HA are highly subsidized (85% to 98%) by the government. 41 The low price of gastroprotection medications might also favor its use for various indications such as prophylaxis of ulcer and bleeding, maintenance therapy for gastroesophageal reflux diseases and non-cardiac chest pain among dabigatran users.
The exact mechanism how gastroprotective agents prevent upper GIB in patients taking dabigatran remains unknown. Whilst the median time to bleeding after the use of dabigatran was approximately one month, the co-administration of PPI or H2RA may reduce the risk of bleeding from pre-existing gastroduodenal ulcers or erosions. Hence, the risk reduction was significantly higher among patients with prior history of peptic ulcer disease/GIB. Another possible explanation for the observed protective effect of gastroprotective agents may be mediated through acid suppression that interferes with absorption of dabigatran. The formulation of dabigatran etexilate contains a tartaric acid core to provide an acidic environment required for drug absorption. 1, 2 It is biologically plausible that the acid suppressive effects of PPIs and
H2RAs reduce the absorption of dabigatran. In the RE-LY trial, PPIs were observed to lower dabigatran exposures by 15%, but did not significantly reduce the overall clinical efficacy. 42 Further study is warranted to assess the potential risk-benefits of gastroprotection in patients on dabigatran by quantifying the risk of thromboembolism versus the benefit of preventing GIB.
Unlike previous randomized controlled studies that had restrictive patient's selection criteria, [2] [3] [4] our results were based on real-life clinical practice, through inclusion of all patients who were prescribed dabigatran. We utilized electronic database resources, which have been recognized to provide powerful platforms to conduct large-scale, real-life drug safety and post-marketing surveillance studies. [43] [44] [45] [46] By using the largest inter-linked clinical database in Hong Kong, we observed a higher risk of dabigatan-related GIB in the Southern Chinese population group (4.2 per 100 person-year) compared to other non-Asians patient groups as reported in Denmark (1.2 to 1.5 per 100 person-year) 37 and in the United States (0.6 to 3.4 per 100 person-year). 7, 47 The higher bleeding risk observed in our study population could not be explained by the dose of dabigatran used, as most (73%) of our patients were using the lower dosage of 220mg/day. In the RE-LY trial, the bleeding risk of Asians was higher than that of non-Asians despite younger age and comparable blood pressure. 48 Similarly findings were reported in a retrospective cohort study of 18,867 AF patients that Asians had a higher risk of intracranial hemorrhage compared with the Whites, Blacks, and Hispanics. 49 A possible mechanistic explanation of this observation could be explained by the genetic differences in blood coagulation between Asians and non-Asians. 48 In particular, the factor V-Leiden mutations, which favors the formation of blood clots, is extremely rare in Asian but more commonly found in other ethnicities. 50, 51 It remains to be determined whether there are considerable ethnic differences on the clearance of drugs or whether the Chinese population is more susceptible to bleeding. 52, 53 Our study has limitations. Similar to other clinical healthcare databases, CDARS does not capture the use of over-the-counter medications such as NSAIDs, which could lead to underestimation of the effect of concurrent medications on bleeding risk. However, in Hong Kong, non-aspirin oral NSAIDs in general are not over-the-counter medications and require a doctor's prescription. 54 Furthermore, the HA is the only publicly-funded primary care in Hong
Kong where services and medications are highly subsidized (85% to 98%) by the government. 41 As a result, it is common for patients with chronic illness requiring long-term medications, such as patients with AF on dabigatran, to attend outpatient clinics of HA for ongoing treatment care rather than obtaining full-cost medications from over-the-counters. 41 Therefore, it is anticipated that the impact of missing of over-the-counter prescriptions would be minimal. As inherent in the retrospective cohort study design based on large population databases, we cannot exclude the possibility of residual confounding factors. In particular, other risk factors for peptic ulcer and bleeding such as Helicobacter pylori status and smoking history were lacking in this database.
To overcome this potential limitation, we have included other possible confounding factors in our Poisson regression and added different sensitivity analyses in this study. The protective effects of PPI or H2RA appeared to be very consistent even after adjustment with indications or dosages of dabigatran and concurrent medical illnesses. With further analysis, the protective effect of gastroprotective agents against GIB was found to be more prominent in patients with prior history of peptic ulcer/GIB. Different sensitivity analyses or sub-analyses supported the consistency of the protective effects of gastroprotective agents.
Our study also did not include control groups or comparator arms including conventional oral anticoagulants such as warfarin. However, several published epidemiological studies and clinical trials have compared dabigatran with traditional therapies, which consistently infer that dabigatran has a comparable or higher risk of GIB when compared to warfarin. [2] [3] [4] 7, 37, [55] [56] [57] Hence, our focus was to characterize the risks and protective factors of GIB associated with dabigatran, particularly in the Chinese population, where similar data are currently lacking. In addition, we could only access the medical records in CMS in a single hospital cluster for data validation, but not in all the seven clusters due to the limited access right. Therefore, potential bias could arise from any systematic differences in coding validity across different clusters. Nevertheless, CMS and CDARS are clinical health record databases. The information stored in CMS and CDARS are used for daily clinical management rather than insurance and reimbursement. Hence, the coding is not linked with any financial rewards or incentives, and the coding practice is most likely to be non-differential between individual patients and hospital clusters, which are under the same management structure of the HA. As in our validation sample, the bleeding rate (35/711 = 4.9%) appeared to be higher compared to the overall rate (2.5%). Since the HKW cluster is a tertiary referral center which tends to have referrals from cross-cluster patients with complex medical problems, the inclusion of these patients may have higher risk of bleeding than other patients. 24 Finally, with a relatively smaller number of infrequent users of gastroprotective agents in this cohort, we cannot exclude the possibility that the non-significant results for the infrequent users were due to insufficient power. Further study is needed to confirm the results.
Conclusions
This study showed that the risk factors of GIB in our patients prescribed with dabigatran included age ≥75, history of peptic ulcer or GIB, and concomitant use of aspirin.
Gastroprotective agents were associated with a reduced risk of GIB in patients on dabigatran.
The protective effect seemed to be more on prevention of upper GIB and among those with a prior history of peptic ulcers or GIB. Hence, gastroprotective agents shall be considered in highrisk patients taking dabigatran. Further prospective randomized clinical trial is warranted to confirm the effect of gastroprotective agents on reducing the risk of GIB in patients using dabigatran. Author names in bold designate shared co-first authors.
